NCT01471145View on ClinicalTrials.gov

Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Opioid-Related DisordersHeroin Dependence
Interventions
DRUG

Naltrexone

naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month

Trial Locations (1)

P.O. Box 22660

Academic Medical Center, Amsterdam

Sponsors

Collaborators (1)

Alkermes, Inc.
All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Alkermes, Inc.

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER